Novo Nordisk Licenses Oral Drug Delivery Tech from Vivtex in $2.1B Deal
Event summary
- Novo Nordisk has entered into a partnership with Vivtex Corporation to develop oral biologic medicines for obesity, diabetes, and related conditions.
- Vivtex is eligible to receive up to $2.1 billion in upfront consideration, research funding, milestone payments, and royalties.
- Novo Nordisk will lead global development and commercialization of any resulting products.
- Vivtex’s GI-ORIS™ platform utilizes high-throughput screening and AI to optimize oral drug delivery.
- The partnership expands Vivtex’s platform into metabolic diseases and leverages Novo Nordisk’s expertise in peptide and protein therapeutics.
The big picture
Novo Nordisk's continued investment in oral drug delivery reflects a strategic shift towards more patient-friendly therapies, potentially expanding market access and reducing reliance on injectable formulations. Vivtex, founded by MIT scientists, represents a novel approach to drug delivery, and this partnership provides significant validation and funding for their technology. The deal underscores the growing importance of AI and automation in drug development, particularly in overcoming bioavailability challenges for biologics.
What we're watching
- Bioavailability
- The success of this partnership hinges on Vivtex’s ability to consistently achieve high oral bioavailability for Novo Nordisk’s biologic drug candidates, a notoriously difficult hurdle.
- Regulatory Approval
- Novo Nordisk’s experience with oral biologics, despite a recent launch, will be critical; regulatory pathways for this class of drugs remain relatively unproven and could introduce delays.
- Commercialization
- The ultimate value of the partnership will depend on Novo Nordisk’s ability to successfully commercialize these oral therapies and capture market share from existing injectable treatments.
Related topics